Navigation Links
Phase II Ibrutinib Monotherapy Study Shows CLL Patients Achieved Rapid and Sustainable Disease Control Irrespective of Age or High Risk Prognostic Factor
Date:4/8/2013

SUNNYVALE, Calif., April 8, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.

This study was discussed at today's American Association for Cancer Research (AACR) annual meeting in Washington, DC together in addition to 8 other presentations covering advances in clinical and pre-clinical research with ibrutinib. The Phase II study, which was sponsored by the National Heart, Lung and Blood Institute, included an analysis of two CLL patient cohorts: the elderly, above 65 years of age, (n=24, of which 8 were treatment naive) and the high risk genetic group with a deletion of chromosome 17p (del 17p) (n=29, of which 15 were treatment naive). Many elderly patients with CLL are unable to tolerate aggressive therapies. Patients with deletion of chromosome 17p typically are poor responders to chemoimmunotherapy and have limited treatment options with no standard of care defined. Of all CLL patients enrolled in this trial, 72% had been characterized as Rai stage 3-4, indicating an advance stage, high risk patient population.

The results of the study were presented by lead investigator Adrian Wiestner , M.D., PhD, Hematology Branch, NHLBI, National Institutes of Health. "Ibrutinib was highly efficacious as a single agent in patients with untreated, relapsed and unresponsive CLL, irrespective of their del 17p status," Dr. Wiestner said. "Responses in this study appear to be durable, and results indicate the drug is effective against the disease in lymph nodes, spleen and
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
2. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
3. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
4. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
5. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
6. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
7. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
8. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
9. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
10. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
11. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium ... technology market intelligence, the United States ... (TEO) device markets will expand moderately through 2022, ... segments. In particular, increasing interest in drug-eluting beads ...
(Date:1/15/2014)... LAVAL, Quebec , Jan. 15, 2014  Valeant Pharmaceuticals ... VRX) announced that the applicable waiting period under the ... to the previously announced tender offer by its indirect ... the outstanding shares of common stock of Solta Medical, ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... NEW YORK, March 16, 2011 Reportlinker.com announces ... in its catalogue: Global ... http://www.reportlinker.com/p098415/Global-Cell/Tissue-Culture-Supplies-Industry.html This report analyzes ... US$ Million by the following Product Segments: Media, ...
... NEW YORK, March 16, 2011 Reportlinker.com announces ... in its catalogue: Global Temperature ... This report analyzes the worldwide ... by the following Product Segments: Digital Thermometers, Infrared ...
Cached Medicine Technology:Global Cell/Tissue Culture Supplies Industry 2Global Cell/Tissue Culture Supplies Industry 3Global Cell/Tissue Culture Supplies Industry 4Global Cell/Tissue Culture Supplies Industry 5Global Cell/Tissue Culture Supplies Industry 6Global Cell/Tissue Culture Supplies Industry 7Global Cell/Tissue Culture Supplies Industry 8Global Cell/Tissue Culture Supplies Industry 9Global Cell/Tissue Culture Supplies Industry 10Global Cell/Tissue Culture Supplies Industry 11Global Cell/Tissue Culture Supplies Industry 12Global Cell/Tissue Culture Supplies Industry 13Global Cell/Tissue Culture Supplies Industry 14Global Cell/Tissue Culture Supplies Industry 15Global Cell/Tissue Culture Supplies Industry 16Global Cell/Tissue Culture Supplies Industry 17Global Cell/Tissue Culture Supplies Industry 18Global Cell/Tissue Culture Supplies Industry 19Global Temperature Monitoring Devices Industry 2Global Temperature Monitoring Devices Industry 3Global Temperature Monitoring Devices Industry 4Global Temperature Monitoring Devices Industry 5Global Temperature Monitoring Devices Industry 6Global Temperature Monitoring Devices Industry 7Global Temperature Monitoring Devices Industry 8Global Temperature Monitoring Devices Industry 9Global Temperature Monitoring Devices Industry 10Global Temperature Monitoring Devices Industry 11Global Temperature Monitoring Devices Industry 12Global Temperature Monitoring Devices Industry 13Global Temperature Monitoring Devices Industry 14Global Temperature Monitoring Devices Industry 15Global Temperature Monitoring Devices Industry 16Global Temperature Monitoring Devices Industry 17Global Temperature Monitoring Devices Industry 18
(Date:4/24/2014)... than one out of three survivors of critical ... The Lancet Respiratory Medicine , and the ... than mentally. , It is one of the ... functional outcomes of critical care survivors, according to ... Medicine, and it highlights a significant public health ...
(Date:4/24/2014)... researcher has found a relationship between motor skill deficiencies ... disorder in very young children. , The findings, ... direct relationship between motor skills and autism severity, indicate ... be included in treatment plans for young children with ... College of Public Health and Human Sciences. , ...
(Date:4/23/2014)... investigators may lead to greater availability and acceptability of ... use of fecal material from healthy donors to treat ... ( C. difficile ) bacteria. In their paper ... Diseases , the researchers report that use of prescreened ... as successful in curing recurrent C. difficile ...
(Date:4/23/2014)... Washington State University Spokane have developed a new ... nod off behind the wheel. , Their recently ... are more variable in drowsy driversand offers an ... video-based driver drowsiness detection systems. , Van Dongen"Video-based ... car is drifting out of its lane are ...
(Date:4/23/2014)... report that rats exposed to high-energy particles, simulating conditions ... show lapses in attention and slower reaction times, even ... ranges. , The cognitive impairments which affected a ... appear to be linked to protein changes in ... to hold true in humans, suggest it may be ...
Breaking Medicine News(10 mins):Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 3Health News:Motor skill deficiencies linked to autism severity in new research 2Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 2Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 3Health News:WSU innovation improves drowsy driver detection 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 3
... eating beef from cattle with mad cow disease may ... individuals, say researchers according to a recent study. ... variant form of Creutzfeldt-Jakob disease (vCJD), which has been ... bovine spongiform encephalopathy (BSE), can be transmitted through an ...
... of aspirin may reduce the risk of colon polyps, which ... women between 34 and 77 years old. The participants underwent ... years, nearly 1,400 of the women were diagnosed with adenoma, ... ,Results show participants who reported taking aspirin regularly were 25-percent ...
... there is a lot of confusion about what type of diet ... a low carbohydrate diet, a new study shows a low fat, ... the amount of food is not restricted. ,For the research, ... alone and in combination with exercise. They looked at body weight ...
... blood may predict the risk of heart attack or death ... new study. ,Researchers conducted a study to determine whether ... for death or non-fatal heart attack in patients with acute ... factor family and it acts as an instigator of hardening ...
... Periodontal disease is a chronic bacterial infection that affects ... research shows a blood test can not only reveal ... periodontal disease risk. ,Researchers from Japan studied ... blood tests that checked for 37 items, including cholesterol ...
... and one that causes excessive absence from work. Many doctors ... returning them to normal activity levels. But many people with ... ,A new study suggests people with low back pain ... was conducted among the employees of an airline company in ...
Cached Medicine News:
... The Bugbox-M incorporates all the familiar and proven ... interface with the Ruskinn gas mixing system.The gas ... - 20% in 0.1% increments), carbon dioxide (0% ... - 10% in 1% increments) components of the ...
The airlock allows anaerobic entry of large flasks, vessels, and up to 90 plates at a time....
The 500 plate capacity MG-500 has an airlock for ease of use and an additional 100 plate capacity. Refrigeration is also available for growth of psychrophilic organisms...
... the operating theatre is ready for all current ... Its modern design allows a quick, problem-free conversion ... components are connected securely and sturdily to MARS ... if there should ever be a problem in ...
Medicine Products: